COX2 selective inhibitors were developed in order to preserve the COX I synthesis of physiologically useful prostaglandins responsible for renal and gastrointestinal activities.
However it has been shown that the COX 2 selectivity causes the development of imbalances in the system.
Prostacyclin is a COX2 product is an inhibitor of platelet activation and a vasodilator that counteracts the physiological effects of COX 1 product, Thromboxane which includes thrombosis and vasoconstriction.
Removal of the protective function of prostacyclins increases the risk for cardiovascular events such as stroke, ischemia.
#Thursdaybit . . .
Please Subscribe to continue reading
